Anti-CD73 Antibody and A2A Inhibitor Combination for Tumor Immunosuppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, particularly those using immune-checkpoint inhibitors, have modest clinical benefits due to tumors employing nonoverlapping immunosuppressive mechanisms to evade the immune system, necessitating improved compositions and methods to reduce tumor-mediated immunosuppression.
Innovation Solution
Development of isolated binding molecules, such as antibodies or antigen-binding fragments, specifically targeting CD73, in combination with A2A receptor inhibitors to inhibit tumor growth and enhance anti-tumor immune responses by reducing immunosuppression and metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune-checkpoint inhibitors are used to treat cancer, then anti-tumor immune response is enhanced, but clinical benefits are modest due to tumors employing nonoverlapping immunosuppressive mechanisms
Solution Approach 1:
The patent segments the immunosuppressive mechanism into multiple independent pathways: CD73-mediated adenosine production and A2A receptor signaling. By targeting each pathway separately with specific antibodies and inhibitors, the therapy can overcome multiple nonoverlapping immunosuppressive mechanisms simultaneously, resolving the contradiction between modest clinical benefit and limited mechanism coverage.
Solution Approach 2:
The patent combines CD73-blocking antibodies with A2A receptor inhibitors into a synergistic therapy regimen. This merging of two agents that target different steps in the same pathway creates a more comprehensive anti-immunosuppressive effect, enhancing clinical benefit by addressing both the enzyme production and the receptor signaling components.
2Reliability
If CD73 expression is elevated in tumors, then immunosuppression is enhanced and patient survival is reduced, but single-agent CD73 inhibition shows limited efficacy
Solution Approach 1:
The patent merges CD73-blocking antibodies with A2A receptor inhibitors to achieve synergistic anti-tumor efficacy. The combination therapy produces greater anti-tumor effect than either agent alone, addressing the limitation of single-agent CD73 inhibition while improving patient survival outcomes.
Solution Approach 2:
The patent ensures continuous disruption of the adenosine signaling pathway by simultaneously blocking CD73 (which produces adenosine) and inhibiting A2A receptors (which respond to adenosine). This continuous action prevents tumor cells from utilizing the adenosine pathway for immunosuppression, thereby improving both anti-tumor efficacy and patient survival.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively increases overall survival, induces tumor-specific immune responses, and reduces metastasis by targeting CD73-mediated immunosuppression, outperforming single-agent treatments in clinical benefits.
Implementation Method 1
CD73 or ecto-5′nucleotidase (5′-NT) is ubiquitously expressed in a number of tissues. This protein is anchored to the cell membrane through a glycosylphosphatidylinositol (GPI) linkage, has ecto-enzyme activity, and plays a role in signal transduction. The primary function of CD73 is the conversion of extracellular nucleotides (e.g., 5′-AMP), to which cells are generally impermeable, to their corresponding nucleosides (e.g., adenosine), which can readily enter most cells.
Implementation Method 2
CD73 production of adenosine by the dephosphorylation of AMP, has been shown to regulate adenosine receptor engagement in many tissues, indicating that adenosine functions in cytoprotection, cell growth, angiogenesis and immunosuppression, and also plays a role in tumorigenesis.
Data Source
AI summary
The present invention provides therapeutic combinations featuring anti-CD73 antibodies (e.g., MEDI9447) and A2A receptor inhibitors and methods of using such combinations for reducing tumor-mediated immunosuppression.